Lakefront Biotherapeutics: A Strategic Pivot Through the Ouro Transaction
Galapagos rebrands as Lakefront, acquires a first-in-class autoimmune asset, and unlocks financial flexibility from Gilead.
GLPG.AS · Earnings Call · 2026-05-07
From Galapagos to Lakefront: A Transformation
The May 7, 2026 call marks a milestone for the company formerly known as Galapagos. CEO Henry Gosebruch opened the call reflecting on his first year: “This call marks my 1-year anniversary as CEO, and I couldn't be more proud of what we've accomplished together in the first year of our journey.” — Henry Gosebruch, Chief Executive Officer (CEO) · 2026-05-07 The transformation is profound: a new name, a new Board Chair with deep pharma BD experience, and a landmark transaction. The company will be listed as LKFT on Nasdaq and Euronext from May 8.
We have transformed our management team and Board, repositioned our portfolio, added an exciting set of new pipeline programs, and we are changing our name to Lakefront Biotherapeutics.
The centerpiece is the binding agreement with Gilead to acquire the portfolio created by Ouro Medicines. The lead program, gamgertamig, is a BCMA/CD3 T cell engager targeting autoimmune diseases. Gosebruch described it as having "multibillion-dollar revenue potential" and highlighted its differentiated profile. The company emphasizes its speed-to-market advantage in rare orphan indications, with registrational trials expected as early as 2027.
Gamgertamig: A Potential First-in-Class Asset
Eric Hedrick, Chief Clinical Adviser, elaborated on the clinical differentiation: “the profile that would be an optimal profile for going into late-stage development would be one where you get profound B cell depletion, but a dose duration schedule that minimizes CRS risk.” — Eric Hedrick, Senior Management or Scientific/Medical Executive · 2026-05-07 The asset has generated compelling data across 60 patients in five distinct autoimmune indications, with rapid inductions of durable complete responses and minimal cytokine release syndrome. The team has also secured Fast Track and Orphan Drug designations in the U.S. for ITP and AHA. This focus on managing infectious risk through dose scheduling is a key differentiator.
Financial Flexibility from Gilead
CFO Aaron Cox detailed the revised OLCA terms: “the participation of Gilead was far above the $150 million expected with the Legacy Agreement.” — Aaron Cox, Senior Management or Business Development Executive · 2026-05-07 The new terms unlock $500 million for broader use, with up to $150 million available for share repurchases. This strengthens the company's ability to deploy capital strategically and pursue further BD opportunities. Combined with a shareholder-approved buyback, the company is signaling a capital-allocation shift.
This pivot marks a departure from the prior strategy of evaluating derisked external assets while balancing internal development. In the prior quarter, Gosebruch stated: “we're focused on opportunities that are clinically derisked. So we're looking at mid- to late-stage opportunities.” — Henry Gosebruch, CEO · 2025-11-06 Now, with the Ouro deal, the company has executed on that vision, and the financial runway has been bolstered.
The company now expects to end 2026 with cash of €1.975–2.05 billion, and even after accounting for R&D spend on gamgertamig until first approval, it retains a majority of its current cash. This gives substantial dry powder for additional "high-hurdle" BD, as Gosebruch noted: “the hurdle for the next BD deal is very, very high.” — Henry Gosebruch, Chief Executive Officer (CEO) · 2026-05-07 The new Ouro transaction also brings three preclinical programs, expanding the pipeline.
In a prior call, the company's capital position was a key highlight: “we have EUR 46 per share in cash and we're trading obviously at a much, much lower number.” — Henry Gosebruch, CEO · 2025-11-06 That gap between cash value and market value underscores the market's skepticism, which this strategic move aims to address. The company is now positioning itself as a capital allocator with a near-term catalyst in gamgertamig and the flexibility to pursue more.
The Proof of Concept in autoimmune diseases is now a clear strategic pillar. With the OLCA modified, the company has moved from a constrained relationship to a more independent posture. This is a genuinely transformative moment, as prior calls showed the company still grappling with internal asset decisions (e.g., 3667) and waiting for BD. Now, Lakefront Biotherapeutics is not just a renamed company; it has fundamentally repositioned itself to create value through disciplined BD, a potential blockbuster autoimmune asset, and a strengthened balance sheet.